Review

The Genetic Epidemiological Landscape of Hip and Knee Osteoarthritis: Where Are We Now and Where Are We Going?

Eleni Zengini, Chris Finan, and J. Mark Wilkinson

ABSTRACT. Osteoarthritis (OA) is a complex disease that affects the whole joint, with multiple biological and environmental factors contributing to its development. The heritable component for primary OA accounts for ~50% of susceptibility. So far, candidate gene studies and genome-wide association scans have established 18 OA-associated loci. These findings account for 11% of the heritability, explaining a rather small fraction of the genetic component. To further unravel the genetic architecture of OA, the field needs to facilitate more precise phenotypic definitions, high genome coverage, and large sample metaanalyses, expecting the identification of rare and low frequency variants with potentially higher penetrance, and more accurate methods for calculating phenotype-genotype correlation. Expression analysis, epigenetics, and investigation of interactions can also help clarify the implicated transcriptional regulatory pathways and provide insights into further novel pathogenic OA mechanisms leading to diagnostic biomarker identification and new, more focused therapeutic disease approaches. (J Rheumatol First Release December 1 2015; doi:10.3899/jrheum.150710)

Key Indexing Terms:
OSTEOARTHRITIS         GENETIC STUDIES           SINGLE-NUCLEOTIDE POLYMORPHISM

Osteoarthritis (OA) is a musculoskeletal disorder that causes degradation of synovial joints. It is the most common joint disease, and most frequently affects the hip, knee, spine, and the small joints of the hand and the foot. OA causes loss of articular cartilage, formation of osteophytes, changes in subchondral bone, and synovitis. It is a complex disease that affects the whole joint, with multiple biochemical, genetic, biological, morphological, biomechanical, and environmental factors contributing to disease occurrence. The heritable contribution to primary OA susceptibility has been established by twin and sibling studies to be about 50% (range 40–65%), and is transmitted in a non-Mendelian manner. OA typically has its onset in mid-to-later life, indicating that age is a susceptibility risk factor. OA is more common in women, particularly following menopause. Sex differences may be partly explained by the suggested involvement of estrogen in cartilage metabolism. OA is also thought to be associated with body mass index, joint injury, and lifestyle. OA has a large effect on society. Psychological and physical disability lead to a substantial economic burden that is expected to grow with the increasing prevalence of OA.

The prevalence of hip and knee OA varies by ethnicity. Asian populations show a higher prevalence for knee OA and a lower prevalence for hip OA in the Chinese and Japanese compared with populations of European descent. These differences in OA prevalence may also indicate genetic heterogeneity. The interplay between genetic and environmental factors in OA is not fully understood and only a small fraction of the genetic component has been explained. The purpose of our perspective article is to review the current genetic epidemiological landscape of OA and to explore future opportunities to further unravel its genetic architecture.

CURRENT FINDINGS IN OA GENETICS

Genetic architecture of OA. As with other common complex disorders, the genetic architecture of OA is underpinned by variants covering a wide range of frequencies and effect sizes. Most established OA-associated variants are represented by common single-nucleotide polymorphism (SNP) with minor allele frequency (MAF) > 5% that have moderate to small effect sizes (OR ~1.1–1.3). The small number of OA loci established to date account for only a small fraction of disease heritability (10.7%; Figure 1). It is also possible to estimate the proportion of the genetic component explained...
by all variants using genome-wide association study summary statistics, with approaches such as Restricted Maximum Likelihood and Phenotype correlation genotype correlation regression\textsuperscript{8,9}. An application in case-control studies suggests that common variants could explain at least half the heritability for common diseases. Low frequency and rare variants (MAF 1–5% and MAF < 1%, respectively), epigenetic changes, structural variants, and gene-environment interactions may also contribute to the missing heritability of OA\textsuperscript{10}.

Established OA loci. Several linkage scans have been conducted for OA, but most have failed to establish replicating allelic loci. Numerous candidate gene studies based on the (to date) limited known biological etiology of OA have been conducted and have also been irreproducible\textsuperscript{3}. Multiple factors, including lack of study power, account for this lack of replication. Exceptionally, \textit{GDF5} that has been associated repeatedly with OA was originally discovered in gene-centric studies. \textit{GDF5} affects chondrogenesis and joint element formation during skeletal development, which are consistent with the protein expression in the cartilage and joint interzone\textsuperscript{11}. A candidate gene study first reported that rs143383 (in the 5' untranslated region) was associated with hip OA in 2 independent Japanese populations (OR 1.79, \(p = 1.8 \times 10^{-13}\))\textsuperscript{12}. The SNP is associated with reduction in \textit{GDF5} transcription in chondrogenic cells, which results in reduced levels of protein expression. This locus was also later found to be associated with OA in European populations\textsuperscript{13}. Genetic variation in \textit{GDF5} was also found to be associated with height\textsuperscript{14}. It is also suggested that lower levels of \textit{GDF5} in mice include mechanisms of altered loading and changes in subchondral bone, exhibiting developmental failure of the condyles and the articular ligaments\textsuperscript{15} (Table 1).

Genome-wide association studies (GWAS) examine hundreds of thousands of SNP across the genome and seek to establish associations with the risk of complex diseases and traits. The insights afforded by these studies can help improve our understanding of the key pathways involved in disease pathogenesis, and may lead to novel approaches to disease diagnosis, treatment, prevention, prognostic markers, and personalized (precision) therapy. In the field of complex disease, thousands of SNP have been robustly associated with disease risk at genome-wide statistical significance (\(p \leq 5 \times 10^{-8}\))\textsuperscript{16}. Several small- and medium-scaled GWAS have been carried out for OA.

A GWAS identified a missense variant, rs7639618, in \textit{DVWA} that is associated with knee OA, and replicated at a genome-wide significant level (\(p = 7.3 \times 10^{-11}\)) in a Japanese and combined Japanese and Han Chinese cohorts in 2008\textsuperscript{17}. \textit{DVWA} is a 276 amino acid protein that binds to β-tubulin, modulating its chondrogenic function\textsuperscript{18}. The gene was also found to be more highly expressed in cartilage than in other human tissues, suggesting an involvement of \textit{DVWA} in the metabolism of cartilage in humans (Table 1).

A further GWAS for knee OA in Japanese participants identified association with further SNP rs7775228 (OR 1.34, 95% CI 1.21–1.49, \(p = 2.43 \times 10^{-8}\)) and rs10947262 (OR 1.32, 95% CI 1.19–1.46; \(p = 6.73 \times 10^{-8}\)) in a region containing HLA class II/III genes (\textit{HLA-DQB1} and \textit{BTNL2}), and was replicated in Europeans\textsuperscript{19}, indicating that immunologic mechanisms may also contribute to OA pathogenesis.

The Treat-OA consortium GWAS reported and replicated...
The arthritis research council Osteoarthritis GENetics (arcOGEN) consortium carried out a 2-stage GWAS, culminating in the largest GWAS in OA to date. The initial hip and knee OA GWAS (sample size: 3177 cases and 4894 controls) and replication performed by the arcOGEN study in the United Kingdom did not identify any loci at genome-wide significance level, underlining the need for larger sample sizes and stricter phenotype definitions of OA given the complexity and heterogeneity of the disease7.

### Table 1. Polymorphisms associated with hip and knee OA.

<table>
<thead>
<tr>
<th>SNP Risk Allele</th>
<th>Nearest Gene(s)</th>
<th>OR</th>
<th>p</th>
<th>Risk AF</th>
<th>Joint Sex Specificity</th>
<th>Ethnic Group</th>
<th>Suggested Functional Relevance to OA</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs143383-T</td>
<td>GDF5</td>
<td>1.79</td>
<td>1.8 × 10^-13</td>
<td>0.74</td>
<td>Hip</td>
<td>Asian</td>
<td>Affects chondrogenesis and joint element formation</td>
</tr>
<tr>
<td>rs143383-T</td>
<td>GDF3</td>
<td>1.16</td>
<td>8.3 × 10^-9</td>
<td>N/A</td>
<td>Knee</td>
<td>Both</td>
<td>European</td>
</tr>
<tr>
<td>rs7639618-G</td>
<td>DVWA</td>
<td>1.43</td>
<td>7.3 × 10^-11</td>
<td>0.63</td>
<td>Knee</td>
<td>Both</td>
<td>Asian</td>
</tr>
<tr>
<td>rs7775228-T</td>
<td>HLA-DQB1</td>
<td>1.34</td>
<td>2.4 × 10^-8</td>
<td>0.62</td>
<td>Knee</td>
<td>Both</td>
<td>Asian</td>
</tr>
<tr>
<td>rs10947262-C</td>
<td>BTN12</td>
<td>1.31**</td>
<td>5.1 × 10^-9**</td>
<td>0.58**</td>
<td>Knee</td>
<td>Both</td>
<td>Asian</td>
</tr>
<tr>
<td>rs3815148-C*</td>
<td>COG5</td>
<td>1.14</td>
<td>8 × 10^-8</td>
<td>0.23</td>
<td>Knee</td>
<td>Both</td>
<td>European</td>
</tr>
<tr>
<td>rs4730250-G</td>
<td>DUS4L</td>
<td>1.17</td>
<td>9.2 × 10^-9</td>
<td>0.17</td>
<td>Knee</td>
<td>Both</td>
<td>European</td>
</tr>
<tr>
<td>rs11842874-A</td>
<td>MCF2L</td>
<td>1.17</td>
<td>2.1 × 10^-8</td>
<td>0.93</td>
<td>Knee and hip</td>
<td>Both</td>
<td>European</td>
</tr>
<tr>
<td>rs12982744-C</td>
<td>DOT1L</td>
<td>1.15</td>
<td>2.2 × 10^-8</td>
<td>0.74</td>
<td>Hip</td>
<td>Males</td>
<td>European</td>
</tr>
<tr>
<td>rs6094710-A</td>
<td>NCOA3</td>
<td>1.28</td>
<td>7.9 × 10^-9</td>
<td>0.04</td>
<td>Hip</td>
<td>Both</td>
<td>European</td>
</tr>
<tr>
<td>rs60976-T</td>
<td>GLTSD1</td>
<td>1.12</td>
<td>7.2 × 10^-11</td>
<td>0.37</td>
<td>Knee and hip</td>
<td>Both</td>
<td>European</td>
</tr>
<tr>
<td>rs11177-A</td>
<td>GNL3</td>
<td>1.12</td>
<td>1.3 × 10^-10</td>
<td>0.38</td>
<td>Knee and hip</td>
<td>Both</td>
<td>European</td>
</tr>
<tr>
<td>rs4836732-C</td>
<td>ASTN2</td>
<td>1.2</td>
<td>6.1 × 10^-10</td>
<td>0.47</td>
<td>Hip</td>
<td>Females</td>
<td>European</td>
</tr>
<tr>
<td>rs9350591-T</td>
<td>FILIP1, SENP6</td>
<td>1.18</td>
<td>2.4 × 10^-9</td>
<td>0.11</td>
<td>Hip</td>
<td>Both</td>
<td>European</td>
</tr>
<tr>
<td>rs10492367-T</td>
<td>KHLDC5, PTTLH</td>
<td>1.14</td>
<td>1.5 × 10^-8</td>
<td>0.19</td>
<td>Hip</td>
<td>Both</td>
<td>European</td>
</tr>
<tr>
<td>rs8534487-G</td>
<td>CHST11</td>
<td>1.13</td>
<td>1.6 × 10^-8</td>
<td>0.34</td>
<td>Hip</td>
<td>Both</td>
<td>European</td>
</tr>
<tr>
<td>rs12107036-G*</td>
<td>TP63</td>
<td>1.21</td>
<td>6.7 × 10^-8</td>
<td>0.52</td>
<td>Knee</td>
<td>Females</td>
<td>European</td>
</tr>
<tr>
<td>rs8044769-C*</td>
<td>FTO</td>
<td>1.11</td>
<td>6.9 × 10^-8</td>
<td>0.5</td>
<td>Knee and hip</td>
<td>Females</td>
<td>European</td>
</tr>
<tr>
<td>rs10948172-G*</td>
<td>SUPT3H, CDC5L</td>
<td>1.14</td>
<td>7.9 × 10^-8</td>
<td>0.29</td>
<td>Knee and hip</td>
<td>Males</td>
<td>European</td>
</tr>
<tr>
<td>rs12982744</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* SNP just below genome-wide significance. ** Values of combined replication. † Values of combined datasets. ‡ Risk allele frequency in Europeans from the 1000 genomes database (www.1000genomes.org). OA: osteoarthritis; SNP: single-nucleotide polymorphism; AF: allele frequency; LD: linkage disequilibrium; N/A: not available.

An additional SNP (rs6094710) situated near NCOA3 was established by a large metaanalysis of hip OA GWAS (OR 1.28, 95% CI 1.18–1.39, p = 7.9 × 10^-9)25. NCOA3 demonstrates reduced expression in OA-affected articular cartilage when compared with macroscopically unaffected cartilage of the same joint. The involvement of NCOA3 expression in the setting of OA remains unclear and needs to be investigated, although involvement in hormonal regulation of bone turnover, such as thyroid hormones and steroids, or the suggested involvement of the gene in chondrocyte mechanotransduction are possibilities22 (Table 1).

Zengini, et al: Prospects in the genetics of OA

www.jrheum.org

Downloaded on April 20, 2022 from www.jrheum.org
The strongest 2 signals established by this study were rs6976 (GLT8D1) and rs11177 (located in GNL3), both on chromosome 3p21.1 and in almost perfect LD with each other (OR for both SNP was 1.12, 95% CI 1.08–1.16, rs6976 p = 7.2 × 10−11, and rs11177 p = 1.3 × 10−10). These 2 loci are associated with both hip and knee OA in both men and women. The association was stronger in subjects with total joint replacement (TJR), illustrating the need to use stricter phenotype OA definitions. Further functional analysis is needed to unravel the underlying mechanisms28 (Table 1).

An intronic SNP (rs4836732) situated in ASTN2 was associated with hip OA in women who had undergone arthroplasty (OR 1.20, 95% CI 1.13–1.27, p = 6.11 × 10−10), also pointing out that stricter phenotype definition can empower analysis28. ASTN2 has been suggested to be involved in the regulation of the neuronal protein ASTN1, but the contribution of the neuronal protein ASTN1 to OA mechanisms needs to be investigated (Table 1).

A further intronic SNP, rs835487 located in the CHST11 gene, was found to be associated with hip OA in TJR subjects with an OR of 1.13 (95% CI 1.09–1.18, p = 1.64 × 10−8) for both sexes combined28. CHST11 is differentially expressed in OA-affected and unaffected cartilage, and the gene is implicated in cartilage development. A further signal at rs9350591 was located between FILIP1 and SENP6. The signal reached genome-wide significance for hip OA (OR 1.18, 95% CI 1.12–1.25, p = 2.42 × 10−6)28. Although there is no suggested related function of FILIP1 or SENP6 in OA etiology yet, COL12A1 resides nearby and is known to be involved in bone formation29. An additional signal rs10492367, which lies between KDHDC5 and PTHLH, was also established as a risk locus for hip OA (OR 1.14, 95% CI 1.09–1.20, p = 1.48 × 10−8)28. PTHR5 has been reported to be involved in mouse skeletal development30 (Table 1).

Three further variants were identified as associated with OA, but narrowly missed genome-wide significance in the arcOGEN study: the intronic variant rs8044769, located in the fat mass- and obesity-associated FTO gene, more highly associated in women; the intronic variant rs12107036 in TP63, more highly associated in women who had undergone TJR; and rs10948172, which lies between SUPT3H and CDC5L, more highly associated in men28. FTO is an established obesity risk locus31. The phenotypic overlap between OA and obesity has been genetically substantiated32, and the involvement of FTO in OA has been shown to be mediated through obesity33. The functional involvement of TP63 in the pathogenesis of OA is unclear, although it is reported to be involved in facial shape development34. The functional involvement of SUPT3H and CDC5L remain undefined in OA, although RUNX2, a closely located gene in extended LD, plays a regulatory role in bone development35 (Table 1).

### FUTURE PROSPECTS

**OA phenotypic definition and endophenotypes.** The site- and sex-specific heterogeneity of OA is reflected in the associated genetic heterogeneity. Of the 18 established OA susceptibility loci, only 1 has been associated with both knee and hand OA, 5 with both knee and hip OA, 7 with hip OA only, and 6 with knee OA only (Table 1). Similarly, 13 loci have been associated with OA in both male and female subjects, 3 in women only, and 2 in men only. The examination of narrower, more homogeneous phenotypic definitions of OA, such as disease severity (e.g., arthroplasty), combined with radiographic severity grading and disability measurements, specific morphological variations, anatomic differences of the affected joints, and stratification by sex can enable understanding of OA mechanisms and lead to novel epigenetic-based therapeutic strategies for OA treatment.

**Epigenetics of OA.** There is existing evidence that implicates the involvement of epigenetic gene expression regulatory mechanisms in the pathophysiology of OA. Several genome-wide methylation studies for hip and knee OA have been conducted to date and most focus on the cartilage28,39,40,41,42. These studies demonstrate differentially methylated regions that include genes that have been associated with OA and distinct clustering of hip and knee samples. The concordance of these studies’ results is limited. Further epigenetic research could enable understanding of cartilage engineering mechanisms and lead to novel epigenetic-based therapeutic strategies for OA treatment.
Determinants of OA. Bone geometry is also thought to be genetically determined and may be a contributory factor. Pistol grip deformity (femoral head shape) and neck shaft angle have been associated with the hip OA phenotype. There is also an association between joint deformities quantified by measuring morphologic indices including alpha angle, triangular index height, lateral center edge angle, and extrusion index on pelvic radiographs with the risk of hip arthroplasty and an endstage OA phenotype. These findings underline the importance of further exploration of the genetic basis of well-defined OA-associated endophenotypes. For example, the OA-associated locus in the DOTLI gene was first discovered through its association with cartilage thickness (measured by joint space width on radiographs) in a relatively small population. The outcomes from the arcOGEN study also suggest that use of precise endophenotypes has the potential to enhance the detection of relevant associations.

Technological and analytical advances. In keeping with other common and complex diseases, the total of 18 OA-associated variants in Asian and European populations are represented by common SNP with moderate to small effect sizes. Some of the established signals do not replicate in all ethnic groups tested so far, even when the power of the replication cohorts is sufficiently high. These findings explain only a modest fraction of the heritable component of OA (Figure 1), although the application of genome-wide methods to assess the proportion of genetic variance explained by SNP is expected to increase this estimate.

The use of high-throughput genotyping and sequencing approaches along with more advanced imputation (for example, using the Haplotype Reference Consortium data: www.haplotype-reference-consortium.org) will enable the interrogation and identification of variants from the full allelic frequency spectrum. Low frequency (MAF 1–5%) and rare variants (MAF < 1%) may have larger effect sizes and point to more functionally relevant regions and causal genes. The bigger the biological effect a gene has, the more likely it is to provide important clues about the underlying disease process. There are several examples of rare variants contributing to complex disease and it is likely that OA susceptibility will also be underpinned by variants across the MAF spectrum. In addition, the focus of OA genetics studies to date has been on biallelic sequence changes. It is likely that copy number variation may also be involved. The decreasing cost of high-depth whole genome sequencing is poised to make high-throughput, large-scale genetic studies possible in the near future.

Integrative analysis. Systematic functional genomics approaches in relevant tissues will help characterize the molecular landscape of OA alongside genetics approaches. To understand and treat this multifunctional and complex chronic disease, analytical approaches need to model disease biology from a holistic perspective. Integrative data analysis including targeted approaches such as transcriptomics, proteomics, metabolomics, and methylomics can help in this regard. These large heterogeneous datasets require integration and support by advanced software methodology and novel analysis tools. This approach necessitates multidisciplinary research, although studies using integrated molecular genome-wide profiling of relevant tissue have thus far been limited. Integrating the range of different approaches in OA research is the next step to unravel the underlying mechanisms of the whole joint failure.

Over the last few years there has been a profound transformation in the ability to identify genes that contribute to musculoskeletal disorders. The OA susceptibility loci established to date point to several biological pathways, but further functional analysis is needed to identify the causal genes and determine their involvement. Identification of the missing heritability could be enhanced through the use of advanced genotyping technologies, imputation, stricter OA phenotypic definitions, and the establishment of larger and better-powered studies and meta-collaborations. Systematic integrative analysis is also expected to lead to a profound transformation in the ability to holistically understand this complex disease. The future opportunities of OA genetic research are brightened by all these novel approaches.

ACKNOWLEDGMENT

We are grateful to Eleftheria Zeggini for commenting on the manuscript.

REFERENCES


